Inovio expands innovate phase 3 for ino-4800, its dna vaccine candidate for covid-19, to include colombia following regulatory authorization

Plymouth meeting, pa., oct. 11, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that it has received authorization from colombia's invima (instituto nacional de vigilancia de medicamentos y alimentos, or the national food and drug surveillance institute), to conduct the phase 3 segment of inovio's global phase 2/3 trial, innovate ( in ovio i no -4800 va ccine t rial for e fficacy) in colombia, for ino-4800, its dna vaccine candidate for covid-19.
INO Ratings Summary
INO Quant Ranking